Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM. Dekkers JF, et al. Among authors: berkers g. Sci Transl Med. 2016 Jun 22;8(344):344ra84. doi: 10.1126/scitranslmed.aad8278. Sci Transl Med. 2016. PMID: 27334259
Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF, Van Mourik P, Vonk AM, Kruisselbrink E, Berkers G, de Winter-de Groot KM, Janssens HM, Bronsveld I, van der Ent CK, de Jonge HR, Beekman JM. Dekkers JF, et al. Among authors: berkers g. J Cyst Fibros. 2016 Sep;15(5):568-78. doi: 10.1016/j.jcf.2016.04.007. Epub 2016 May 5. J Cyst Fibros. 2016. PMID: 27160424 Free article.
β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.
Vijftigschild LA, Berkers G, Dekkers JF, Zomer-van Ommen DD, Matthes E, Kruisselbrink E, Vonk A, Hensen CE, Heida-Michel S, Geerdink M, Janssens HM, van de Graaf EA, Bronsveld I, de Winter-de Groot KM, Majoor CJ, Heijerman HG, de Jonge HR, Hanrahan JW, van der Ent CK, Beekman JM. Vijftigschild LA, et al. Among authors: berkers g. Eur Respir J. 2016 Sep;48(3):768-79. doi: 10.1183/13993003.01661-2015. Epub 2016 Jul 28. Eur Respir J. 2016. PMID: 27471203 Free article. Clinical Trial.
Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function.
de Winter-de Groot KM, Janssens HM, van Uum RT, Dekkers JF, Berkers G, Vonk A, Kruisselbrink E, Oppelaar H, Vries R, Clevers H, Houwen RHJ, Escher JC, Elias SG, de Jonge HR, de Rijke YB, Tiddens HAWM, van der Ent CK, Beekman JM. de Winter-de Groot KM, et al. Among authors: berkers g. Eur Respir J. 2018 Sep 17;52(3):1702529. doi: 10.1183/13993003.02529-2017. Print 2018 Sep. Eur Respir J. 2018. PMID: 30166324 Free article.
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis.
Berkers G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, Arets HGM, Marck-van der Wilt REP, Dijkema JS, Vanderschuren MM, Houwen RHJ, Heijerman HGM, van de Graaf EA, Elias SG, Majoor CJ, Koppelman GH, Roukema J, Bakker M, Janssens HM, van der Meer R, Vries RGJ, Clevers HC, de Jonge HR, Beekman JM, van der Ent CK. Berkers G, et al. Cell Rep. 2019 Feb 12;26(7):1701-1708.e3. doi: 10.1016/j.celrep.2019.01.068. Cell Rep. 2019. PMID: 30759382 Free article.
Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations.
de Winter-de Groot KM, Berkers G, Marck-van der Wilt REP, van der Meer R, Vonk A, Dekkers JF, Geerdink M, Michel S, Kruisselbrink E, Vries R, Clevers H, Vleggaar FP, Elias SG, Heijerman HGM, van der Ent CK, Beekman JM. de Winter-de Groot KM, et al. Among authors: berkers g. J Cyst Fibros. 2020 Jul;19(4):614-619. doi: 10.1016/j.jcf.2019.10.022. Epub 2019 Nov 15. J Cyst Fibros. 2020. PMID: 31735562 Free article.
CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank.
Geurts MH, de Poel E, Amatngalim GD, Oka R, Meijers FM, Kruisselbrink E, van Mourik P, Berkers G, de Winter-de Groot KM, Michel S, Muilwijk D, Aalbers BL, Mullenders J, Boj SF, Suen SWF, Brunsveld JE, Janssens HM, Mall MA, Graeber SY, van Boxtel R, van der Ent CK, Beekman JM, Clevers H. Geurts MH, et al. Among authors: berkers g. Cell Stem Cell. 2020 Apr 2;26(4):503-510.e7. doi: 10.1016/j.stem.2020.01.019. Epub 2020 Feb 20. Cell Stem Cell. 2020. PMID: 32084388 Free article.
Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation.
Burghard MM, Berkers GG, Ghijsen SS, Hollander-Kraaijeveld FF, de Winter-de Groot KK, van der Ent CK, Heijerman HH, Takken TT, Hulzebos HE. Burghard MM, et al. Among authors: berkers gg. Pediatr Pulmonol. 2020 Jun;55(6):1400-1405. doi: 10.1002/ppul.24745. Epub 2020 Mar 31. Pediatr Pulmonol. 2020. PMID: 32233113 Free PMC article.
Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation.
Berkers G, van der Meer R, van Mourik P, Vonk AM, Kruisselbrink E, Suen SW, Heijerman HG, Majoor CJ, Koppelman GH, Roukema J, Janssens HM, de Rijke YB, Kemper EM, Beekman JM, van der Ent CK, de Jonge HR. Berkers G, et al. J Cyst Fibros. 2020 Nov;19(6):955-961. doi: 10.1016/j.jcf.2020.04.014. Epub 2020 Jun 1. J Cyst Fibros. 2020. PMID: 32499204 Free article. Clinical Trial.
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
Berkers G, van der Meer R, Heijerman H, Beekman JM, Boj SF, Vries RGJ, van Mourik P, Doyle JR, Audhya P, Yuan ZJ, Kinnman N, van der Ent CK. Berkers G, et al. J Cyst Fibros. 2021 Sep;20(5):761-767. doi: 10.1016/j.jcf.2020.11.007. Epub 2020 Nov 26. J Cyst Fibros. 2021. PMID: 33249003 Free article. Clinical Trial.
Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation.
Kristensen MI, de Winter-de Groot KM, Berkers G, Chu MLJN, Arp K, Ghijsen S, Heijerman HGM, Arets HGM, Majoor CJ, Janssens HM, van der Meer R, Bogaert D, van der Ent CK. Kristensen MI, et al. Among authors: berkers g. J Pers Med. 2021 Apr 27;11(5):350. doi: 10.3390/jpm11050350. J Pers Med. 2021. PMID: 33925519 Free PMC article.
Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.
Muilwijk D, de Poel E, van Mourik P, Suen SWF, Vonk AM, Brunsveld JE, Kruisselbrink E, Oppelaar H, Hagemeijer MC, Berkers G, de Winter-de Groot KM, Heida-Michel S, Jans SR, van Panhuis H, van der Eerden MM, van der Meer R, Roukema J, Dompeling E, Weersink EJM, Koppelman GH, Vries R, Zomer-van Ommen DD, Eijkemans MJC, van der Ent CK, Beekman JM. Muilwijk D, et al. Among authors: berkers g. Eur Respir J. 2022 Aug 18;60(2):2100508. doi: 10.1183/13993003.00508-2021. Print 2022 Aug. Eur Respir J. 2022. PMID: 35086832 Free PMC article.
FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
de Poel E, Spelier S, Hagemeijer MC, van Mourik P, Suen SWF, Vonk AM, Brunsveld JE, Ithakisiou GN, Kruisselbrink E, Oppelaar H, Berkers G, de Winter de Groot KM, Heida-Michel S, Jans SR, van Panhuis H, Bakker M, van der Meer R, Roukema J, Dompeling E, Weersink EJM, Koppelman GH, Blaazer AR, Muijlwijk-Koezen JE, van der Ent CK, Beekman JM. de Poel E, et al. Among authors: berkers g. J Cyst Fibros. 2023 May;22(3):548-559. doi: 10.1016/j.jcf.2023.03.004. Epub 2023 May 3. J Cyst Fibros. 2023. PMID: 37147251